INTRODUCTION
We describe an infant undergoing extracorporeal membrane oxygenation (ECMO) who developed an obstructive aortic thrombus, which was associated with acute renal failure. Treatment with systemic tissue plasminogen activator (t-PA) resulted in lysis of the clot nd improvement in renal perfusion without functional recovery. To our knowledge, this is the first report of thrombolytic therapy in an infant on ECMO.
CASE REPORT
Our patient was a 2.3-kg female born at 39 weeks' gestation. A left congenital diaphragmatic hernia was diagnosed antenatally by sonogram. The infant was born by normal vaginal delivery, and the trachea was intubated immediately after birth for respiratory distress and initiation of mechanical ventilation. An umbilical artery catheter was placed and roentgenogram confirmed the catheter tip position to be at the third lumbar vertebra. Heparin, 1 unit/ml, was added to the umbilical artery catheter fluids. As it was thought likely that the infant would require ECMO, she was transferred to the Children's Hospital of Buffalo a few hours after birth. Initial respiratory support included conventional mechanical ventilation, exogenous surfactant, and inhaled nitric oxide at 10 ppm. Antibiotic therapy was started but discontinued after 48 hours when cultures came back negative. The patient had a relatively stable course during the first 4 days of life. Her condition then worsened and a severe deterioration in oxygenation led to a trial of high-frequency oscillatory ventilation without clinical improvement. She was therefore cannulated for veno-arterial ECMO through the right carotid artery and internal jugular vein, when she was almost 5 days old. Anticoagulation was achieved by infusion of heparin starting at 25 units/kg per hour. The dose was adjusted according to hourly activated clotting time (ACT) measurements aiming to maintain ACT values from 180 to 220 seconds. The ACT values, as well as other coagulation parameters and ECMO pump flow rates, are shown in Table 1 .
After 2 days of ECMO, the patient developed oliguria and hypertension. Abdominal color duplex ultrasound identified no arterial or venous thrombi and normal renal arterial and venous flow. Continuous arteriovenous hemofiltration was started to improve fluid balance. Oliguria progressed to anuria over the next 3 days. A repeat ultrasound examination on the seventh day of ECMO revealed a thrombus in the abdominal aorta from the level of the diaphragm down to the bifurcation ( Figure 1 ) and profound ischemia of both kidneys. The umbilical artery catheter was removed. Hemodialysis was started on the eighth day of ECMO for progressive uremia. Serial ultrasound examinations of the clot showed no change in the clot size.
After consultation with Dr. Maureen Andrew at the International Thrombophilia Programme (1-800-NOCLOTS), treatment with systemic recombinant t-PA (Activase 1 , Genentech, Inc., San Francisco, CA) was started at 0.5 mg/kg per hour on the 12th day of ECMO. Fresh frozen plasma was infused at 1 ml/kg per hour during the t-PA infusion, and the heparin infusion was continued as before.
There was no noticeable bleeding from surgical sites during the t-PA infusion. Following 12 hours of t-PA, a repeat ultrasound examination revealed no visible clot in the aorta (Figure 2 ). Renal arterial and venous flow was markedly improved after thrombolysis, although the patient remained anuric. Neurologic examination and serial head ultrasound examinations before and after thrombolytic therapy were normal.
The patient went on to develop progressive consolidation of the right lung as well as hemodynamic instability. Further care was considered futile and support was withdrawn after 18 days of ECMO, 7 days after the thrombolytic therapy.
DISCUSSION
The frequency of vascular complications associated with the use of umbilical arterial catheters is high regardless of the catheter type or position.
1,2
Addition of low doses of heparin to the catheter infusate may prolong catheter patency, which is probably linked to the presence of a local thrombus. 3 It is likely that the aortic thrombosis in our patient was related to the umbilical arterial catheter, although it is plausible that the thrombosis was an extension of a disseminated intrarenal thrombus secondary to renal injury. There were symptoms of renal failure before thrombus could be detected by ultrasound, and return of renal blood flow after thrombolysis, but no return of renal function. The incidence of aortic thrombus development in fully heparinized patients is not known, but should be low. Mortality rates for infants whose aortic thrombus encompasses both renal arteries may be as high as 100%. 4 Several reports have shown that the use of fibrinolytic therapy for aortic thrombosis in neonates can be safe and effective.
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Continuous hemofiltration is a convection-based form of extracorporeal therapy that is useful for treatment for critically ill neonates who require supportive renal care. 17, 18 The indication in this case was to allow a controlled and gradual correction of fluid overload. Although hemofiltration, by itself, is not known to be a risk factor for the formation of an arterial thrombus, it is possible that in our case it was a contributing factor. 
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Hemorrhagic risks associated with fibrinolytic therapy are likely to be higher in a heparinized patient. We chose t-PA over alternative fibrinolytic agents such as urokinase because it has a short plasma half-life and it induces clot-selective fibrinolysis without producing a widespread systemic fibrinolysis because it is``fibrin specific,'' and becomes more effective after binding to fibrin within a thrombus. 19, 20 This may result in lower frequency of hemorrhagic complications compared to urokinase and streptokinase treatment. 8 The efficacy of t-PA therapy is dependent on adequate plasma concentration of plasminogen. Supplementation with plasminogen in the form of FFP, as was done in our infant, increases the thrombolytic effects. 21, 22 There are few available guidelines for diagnostic and therapeutic approaches to thromboembolic diseases in pediatric patients, 23 and the use of thrombolytic therapy varies widely between centers. 8, 24 Despite this, there is a rapidly growing experience with thrombolytic therapy in neonates 13, 14 even with systemic heparinization. Thromboembolic complications are common in neonates supported by ECMO. 25 ECMO support could be considered a strong relative contraindication to thrombolysis due to the surgical cannulation wound, heparinization, and relatively high background incidence of bleeding complications, such as intracranial hemorrhage. However, the thromboembolic phenomenon was so severe in our infant that we elected to administer thrombolytic therapy. To our knowledge, this is the first report of thrombolytic therapy in a neonate on ECMO. The goal of lysing the aortic and renal vessel thrombi was achieved within 12 hours, and we documented an improvement in renal perfusion immediately after the t-PA was discontinued. Despite clot resolution, the kidneys never regained function, and the patient died when support was withdrawn due to severe lung disease.
Our case report raises issues on the risk/benefit ratio of thrombolytic therapy during ECMO. This complicated issue needs to be further evaluated through multicentered clinical trials and data registry such as that of the Extracorporeal Life Support Organization or the Canadian and International Registry of Neonatal Thrombosis. 24, 25 
